Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555321 · ClinicalTrials.gov registry record · Phase 2
Belatacept in Liver Transplant Recipients
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT00555321: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00555321 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555321, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant
Primary Outcome
Any AR that was clinically suspected and biopsy proven (by central pathologist) was included in this triple composite end point. All biopsies for suspected AR were assessed by a blinded central histopathologist using Banff grading schema. Graft loss was defined as impairment of liver function to such a degree that the participant died or underwent re-transplantation. For 95% (confidence interval) CI within each group, normal approximation is used if N\>=5, otherwise exact method is used.
Interventions
- DRUG Tacrolimus
- DRUG Mycophenolate Mofetil (MMF)
- DRUG Basiliximab
- DRUG Belatacept More Intensive (MI)
- DRUG Belatacept Less Intensive (LI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Why NCT00555321 stopped before completion
NCT00555321 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus is the first listed.
NCT00555321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00555321 about?
NCT00555321 is a clinical study titled "Belatacept in Liver Transplant Recipients". The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant
What is the current status of trial NCT00555321?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2008-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00555321?
The interventions under investigation include: Tacrolimus (DRUG), Mycophenolate Mofetil (MMF) (DRUG), Basiliximab (DRUG), Belatacept More Intensive (MI) (DRUG), Belatacept Less Intensive (LI) (DRUG).
Who is sponsoring clinical trial NCT00555321?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00555321's enrollment target sits among peer trials
260 210th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia